As Low As $0
Out of Pocket
co-pay-caret
XEOMIN® - Clinical Trials for Chronic Sialorrhea

Adults With Chronic Sialorrhea

Disease
Overview
Clinical
Trial
Efficacy Safety Dosing

Clinical Trial

Randomized, Double-Blind, Placebo-Controlled Trial of XEOMIN in Adult Patients With Chonic Sialorrhea1

Clinical trial of XEOMIN in Adult Patients with Chonic Sialorrhea

*XEOMIN is only approved for chronic sialorrhea in adults at the 100-unit dose. The 75-unit dose was not statistically better than placebo.

Reference

  1. Jost W, Friedman A, Michel O, et al.SIAXI: Efficacy and safety of Xeomin (incobotulinumtoxinA) for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions: results of a phase 3 study. Presented at: 70th Annual American Academy of Neurology Meeting; April 22, 2018.;Los Angeles, CA.